The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies
| Autor: | Clara Serrano-Novillo, Antonio Felipe, Mireia Pérez-Verdaguer, Jesusa Capera, Daniel Sastre, Irene Estadella |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Clinical Biochemistry Inflammation complex mixtures Autoimmune Diseases 03 medical and health sciences Immune system Neoplasms Drug Discovery medicine Potassium Channel Blockers Animals Humans natural sciences Obesity Pharmacology Kv1.3 Potassium Channel urogenital system Cell growth business.industry Cancer Potassium channel blocker Voltage-gated potassium channel medicine.disease Potassium channel 030104 developmental biology nervous system Apoptosis Immunology Molecular Medicine biological phenomena cell phenomena and immunity medicine.symptom business Neuroscience medicine.drug |
| Zdroj: | Expert opinion on therapeutic targets. 20(5) |
| ISSN: | 1744-7631 |
| Popis: | The voltage-dependent potassium channel Kv1.3 is mainly present in the nervous and immune systems. In leukocytes, Kv1.3 fine-tunes the activation and proliferation of the immune response. However, Kv1.3 is also present in other tissues where its physiological role is still under investigation. Thus, Kv1.3 alterations have been related to several human diseases.In this work, the authors highlight the role of Kv1.3 in various pathologies and the potential use of Kv1.3 blockers as safe pharmacological tools. The limited repertoire of K(+) channels in leukocytes and its expression pattern makes Kv1.3 crucial for effector memory T cell physiology and it is therefore a good pharmacological target for chronic inflammatory diseases. Moreover, Kv1.3 has been related to insulin sensitivity, cell proliferation and apoptosis. In this scenario, Kv1.3 activity is also implicated in non-insulin-dependent type II diabetes mellitus, obesity and cancer.Fortunately, Kv1.3 is characterized by a very selective and potent pharmacology that has been demonstrated to ameliorate autoimmune and metabolic symptoms in disease-animal models without major side effects. Moreover, Kv1.3 blockers are showing positive results in preclinical trials. Considering this evidence, the implication of Kv1.3 in a wide repertoire of human pathologies indicates this channel is an important therapeutic target. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|